Efficacy of Helicobacter pylori Eradication for the Treatment of Chronic or Persistent Immune Thrombocytopenic Purpura Patients with Moderate Thrombocytopenia: Multicenter Prospective Randomized Phase 3 Study.

Seoul National University Bundang Hospital0 个研究点目标入组 54 人开始时间: 待定最近更新: 2019年3月11日

试验速览

暂无简介。

•Age = 19 years
•Persistent or chronic ITP patients defined by international working group
•30 X 10^9/L = platelet level = 80 X 10^9/L
•H. pylori infection should be confirmed by at least one of tests: urea breath test (UBT), CLO, stool H. pylori Ag, H. pylori in gastric tissue (reported by a trained pathologist)
•No history of any ITP treatment for the past 3 months
•No previous history of H. pylori eradication treatment
•Patients who voluntarily participate in this study and with informed consents

•patients who have any cause of thrombocytopenia such as HIV, HCV infection, lymphoproliferative disease, malignant neoplasm, liver disease, definite SLE and other autoimmune diseases, drugs, MDS and leukemia
•uncontrolled hypothyroidism or hyperthyroidism
•active bleeding for the past 3 months or history of hemorrhagic gastric ulcer or brain hemorrhage
•active infection
•patients who are taking anticoagulant or aspirin
•patients with penicillin allergy or side effects of macrolide
•patients who are taking mizolastine, terfenadine, cisapride, pimozide, astemizole, ergot alkaloid and its derivatives (ergotamine and dihydroergotamine), bepridil or atazanavir
•patients who have known allergy or severe side effect on study drugs
•pregnant or lactating women

发起方